All Eradivir articles
-
NewsEradivir closes $10.25M Series A funding round for next stage of influenza therapeutic trials
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round which will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
